A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

SAN DIEGO -- An algorithm-based decision tool eliminated inappropriate prescribing of bone-modifying agents (BMA) in patients with advanced prostate cancer, according to a VA-based study. Prior to ...

In cases of clinical equipoise, the highest MMAI score quartile could guide selective treatment intensification among patients with high-risk nonmetastatic prostate cancer. An artificial ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...

The questionnaire, called the “Functional Assessment of Cancer Therapy-Radionuclide Therapy,” is a 15-question survey that prompts patients to report on the symptoms and side effects associated with ...

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology “The breadth and depth of Decipher-focused data ...